Journal for ImmunoTherapy of Cancer (Feb 2022)
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
- Xuan Wang,
- Sheng Yao,
- Jie Dai,
- Li Zhou,
- Hui Feng,
- Jun Guo,
- Xue Bai,
- Lu Si,
- Bixia Tang,
- Chuanliang Cui,
- Xinan Sheng,
- Siming Li,
- Zhihong Chi,
- Lili Mao,
- Bin Lian,
- Xieqiao Yan,
- Yan Kong,
- Xiaowen Wu,
- Xiongwen Tang,
- Keith T Flaherty
Affiliations
- Xuan Wang
- Baylor Institute for Immunology Research, Dallas, Texas, USA
- Sheng Yao
- Department of Neurology, Sixth Medical Center of PLA General Hospital, Beijing, China
- Jie Dai
- Aff28 grid.418961.30000000404722713Regeneron Tarrytown NY USA
- Li Zhou
- Department of Acupuncture and Moxibustion, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei, China
- Hui Feng
- Aff1 grid.64924.3d0000000417605735Cancer Center, The First HospitalJilin University 130061 ChangchunJilin China
- Jun Guo
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China
- Xue Bai
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China
- Lu Si
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China
- Bixia Tang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China
- Chuanliang Cui
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China
- Xinan Sheng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- Siming Li
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- Zhihong Chi
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China
- Lili Mao
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China
- Bin Lian
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China
- Xieqiao Yan
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- Yan Kong
- School of General Practice, Guangxi Medical University, Nanning, Guangxi, China
- Xiaowen Wu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China
- Xiongwen Tang
- Medical Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, China
- Keith T Flaherty
- Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA
- DOI
- https://doi.org/10.1136/jitc-2021-004036
- Journal volume & issue
-
Vol. 10,
no. 2
Abstract
No abstracts available.